Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A prognostic diagnostic marker claudin22 for ovarian cancer and its application

A diagnostic marker, ovarian cancer technology, applied in the field of clinical analysis, can solve the problems of no specific research on the correlation between Claudin22 and the prognosis of gynecological tumors, no other family members, etc.

Active Publication Date: 2022-04-22
ZHEJIANG CANCER HOSPITAL
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is currently no research related to the occurrence and development of other family members and tumors, let alone the research on the prognosis of Claudin22 and gynecological tumors. Therefore, this application will be based on the previous research on the relationship between Claudin22 and gynecological tumors and Clinical application value for research and development

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A prognostic diagnostic marker claudin22 for ovarian cancer and its application
  • A prognostic diagnostic marker claudin22 for ovarian cancer and its application
  • A prognostic diagnostic marker claudin22 for ovarian cancer and its application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] Embodiment 1 sample preparation

[0024] 1. Sample collection

[0025]This study collected 38 patients diagnosed with epithelial ovarian cancer in Zhejiang Cancer Hospital from October 2008 to July 2014. All patients received standard treatment: initial tumor cytoreductive surgery or initial staging Surgery plus 6-8 courses of first-line chemotherapy after surgery (platinum combined with paclitaxel), divided according to tumor tissue types: 1. Serous adenocarcinoma; 2. Mucinous adenocarcinoma; 3. Endometrioid adenocarcinoma; 4. Clear cell 5. Unclassified adenocarcinoma; 6. Transitional cell carcinoma; 7. Two or more mixed carcinomas. The clinicopathological data of each patient were carefully collected, and the patients were followed up by telephone after the treatment. The last follow-up time was April 2020, and the patients were followed up for 11-134 months.

[0026] 2. Definitions of relevant indicators such as recurrence, chemotherapy sensitivity, and chemothera...

Embodiment 2

[0037] Embodiment 2 experimental method

[0038] 1. Immunohistochemistry

[0039] 1) Two senior pathologists will repeat the paraffin sections before conducting follow-up experiments.

[0040] 2) Dewaxing and hydration: Soak the slices in xylene solution for 3 times, 10 minutes each time. After taking it out, soak it in 95% alcohol for 5 minutes, and then soak it in 75% alcohol for 5 minutes. Finally, soak in 50% alcohol for 5 minutes. Take out the slices and soak in distilled water.

[0041] 3) Blocking endogenous peroxidase: soak the dewaxed and hydrated sections in methanol solution containing 3% hydrogen peroxide for 15 minutes. Then rinse with PBS solution 3 times, 5 minutes each time.

[0042] 4) Microwave antigen retrieval: immerse the slice in a buffer solution containing EDTA and citrate, put it in a microwave oven, maintain 100% power for 8 minutes, 80% power for 6 minutes, and 60% power for 6 minutes; Then replenish the buffer in time. After cooling, the slic...

Embodiment 3

[0055] Example 3 Claudin22 expression is associated with poor prognosis

[0056] According to the above definition, immunohistochemical experiments were performed on the expression of Claudin22 in the cases, and the statistics were scored after scoring. The specific results are shown in Table 2

[0057] Table 2 Correlation between Claudin22 expression and clinicopathological parameters

[0058]

[0059] Claudin22 is mainly expressed in the cytoplasm of ovarian cancer cells, and the coloring is brown or brown ( figure 1 ). We found that 56.3% (18 / 32) of pathologically poorly differentiated patients in ovarian cancer with low expression of Claudin22 were higher than 43.7% (14 / 32) of highly differentiated patients, with a statistical difference (P=0.047). From the perspective of prognosis, the PFS and OS of ovarian cancer patients with low Claudin22 expression were significantly better than those with high Claudin22 expression (P=0.02, P=0.02, figure 2 ).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention is a prognostic and diagnostic marker Claudin22 for ovarian cancer and its application. For the first time, it is found that the expression level of ovarian cancer drug resistance marker Claudin22 is related to the prognosis of ovarian cancer, specifically when Claudin22 is highly expressed, progression-free survival and overall survival Among the medium prognostic indicators, ovarian cancer cases show poor prognosis, that is, the discovery of the present invention provides prognosis hints for clinical treatment of ovarian cancer including chemotherapy and surgical treatment.

Description

technical field [0001] The present invention belongs to the field of molecular biology, specifically relates to the field of diagnosis / grading / staging and prognosis of cancer, more specifically, the present invention relates to the field of ovarian cancer. The present invention also relates to the fields of ovarian cancer diagnosis, grading, staging and prognosis including the expression of biomarkers, and also provides related analytical reagents, diagnostic models, test kits and clinical analysis. Background technique [0002] Ovarian cancer is the gynecological tumor with the highest mortality rate among women in my country. According to the China Cancer Annual Report, there were about 52,100 new patients in 2015, and about 22,500 people died of ovarian cancer in the same year. With the aging population in my country, the incidence of ovarian cancer is increasing year by year, and the age of onset tends to be younger. Globally, the incidence of ovarian cancer ranks third...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): G01N33/577G01N33/574
CPCG01N33/577G01N33/57484G01N33/57449G01N2333/705
Inventor 施亮傅志勤杨悦周陈西俞婷婷鲁超黄萍
Owner ZHEJIANG CANCER HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com